BELVIQ (lorcaserin hydrochloride) is a serotonin 2C receptor agonist for oral administration used for chronic weight management. Lorcaserin is a highly selective 5-HT2C receptor agonist developed for the treatment of obesity. In rats, lorcaserin led to dose-dependent wt. loss. Lorcaserin proved safe and well tolerated in healthy volunteers and obese patients. In a phase II clin. study, patients administered 20 mg/day lorcaserin achieved an av. wt. loss of 3.6 kg (7.9 lbs), which was significantly greater than the av. wt. loss of 0.3 kg (0.7 lbs) in the placebo group. A phase III clin. trial is ongoing to evaluate the long-term safety and efficacy of lorcaserin in patients with obesity.